Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Stem Cell Therapy for Tissue Regeneration

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...

Venous Thrombosis I: Introduction

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...

Regulation of Hematopoietic Stem Cells

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...

Tissue Transplantation

Tissue Transplantation

Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The Unique Impact of the Atomic Bomb on Modern Hematology

Turkish journal of haematology : official journal of Turkish Society of Haematology·2026

Same author

Extracorporeal photopheresis for the treatment of chronic graft versus host disease.

Hematology (Amsterdam, Netherlands)·2022

Same author

Interleukin-21 and Interleukin-32 gene expression levels and their relationship with clinicopathological parameters in colorectal cancer.

Annali italiani di chirurgia·2022

Same author

ISH initiatives for global hematology education and potential opportunities for sponsorships.

Hematology (Amsterdam, Netherlands)·2015

Same author

ISH 2014 World Congress: report of the Chair of Council.

Hematology (Amsterdam, Netherlands)·2014

Same author

Deep Vein Thrombosis Following Non-myeloablative Allogeneic Stem Cell Transplantation: Presentation of Three Cases and Literature Review.

Turkish journal of haematology : official journal of Turkish Society of Haematology·2014

Search research articles

Related Experiment Video

Updated: May 23, 2026

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice

Published on: December 8, 2023

Thrombosis in stem cell transplantation.

¹Hacettepe University Institute of Oncology, Hematopoietic Stem Cell Transplantation Unit, Ankara, Turkey. eminkansu47@gmail.com

Hematology (Amsterdam, Netherlands)

|April 18, 2012

Summary

This summary is machine-generated.

Stem cell transplant patients frequently experience thrombotic events, including catheter-related thrombosis, venous thromboembolism (VTE), sinusoidal obstructive syndrome (SOS), and transplant-associated thrombotic microangiopathy (TAM). Early diagnosis and management are crucial for improving outcomes in these high-risk patients.

More Related Videos

An Enzymatic Method to Rescue Mesenchymal Stem Cells from Clotted Bone Marrow Samples

An Enzymatic Method to Rescue Mesenchymal Stem Cells from Clotted Bone Marrow Samples

Published on: April 12, 2015

Stem Cell Transplantation in an in vitro Simulated Ischemia/Reperfusion Model

Stem Cell Transplantation in an in vitro Simulated Ischemia/Reperfusion Model

Published on: November 5, 2011

Related Experiment Videos

Last Updated: May 23, 2026

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice

Published on: December 8, 2023

An Enzymatic Method to Rescue Mesenchymal Stem Cells from Clotted Bone Marrow Samples

An Enzymatic Method to Rescue Mesenchymal Stem Cells from Clotted Bone Marrow Samples

Published on: April 12, 2015

Stem Cell Transplantation in an in vitro Simulated Ischemia/Reperfusion Model

Stem Cell Transplantation in an in vitro Simulated Ischemia/Reperfusion Model

Published on: November 5, 2011

Area of Science:

Hematology
Transplantation Medicine
Oncology

Background:

Thrombotic events and hemostatic changes are common complications in stem cell transplant recipients.
These complications significantly contribute to patient morbidity and mortality.
Thrombotic events are categorized into four main types: catheter-related thrombosis, venous thromboembolic (VTE) events, sinusoidal obstructive syndrome (SOS)/veno-occlusive disease, and transplant-associated thrombotic microangiopathy (TAM).

Purpose of the Study:

To review the incidence, risk factors, diagnosis, and management of major thrombotic complications following hematopoietic stem cell transplantation (HSCT).
To highlight the clinical significance and therapeutic strategies for catheter-related thrombosis, VTE, SOS, and TAM.

Main Methods:

Literature review of thrombotic complications in HSCT patients.
Analysis of incidence rates, risk factors, diagnostic modalities, and treatment approaches for each type of thrombotic event.
Discussion of histopathological features and clinical presentation of SOS and TAM.

Main Results:

Catheter-related thrombosis occurs in 8-20% of autologous HSCT patients. VTE incidence is 3.7% within one year, with risk factors including malignancy and central venous catheters.
SOS affects 50-60% of HSCT patients, with high mortality in severe cases; risk factors include prior chemotherapy and hepatic damage. Defibrotide shows efficacy in high-risk SOS.
TAM incidence ranges from 0.5-76%, with high mortality. Current therapies are limited, but trials with complement inhibitors like eculizumab are ongoing.

Conclusions:

Thrombotic complications represent a significant challenge in HSCT, necessitating vigilant monitoring and tailored management strategies.
Understanding the specific characteristics and risk factors for each thrombotic entity is essential for timely intervention.
Ongoing research into novel therapies, such as complement inhibitors for TAM, holds promise for improving patient outcomes.